Hypersensitivity of platelets to adenosine diphosphate in patients with stable cardiovascular disease predicts major adverse events despite antiplatelet therapy

References

• Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86
   PubMed Web of Science ®Google Scholar
• Frossard M, Fuchs I, Leitner JM, Hsieh K, Vlcek M, Losert H, Domanovits H, Schreiber W, Laggner AN, Jilma B. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 2004; 110: 1392–1397
   PubMed Web of Science ®Google Scholar
• Wang JC, Aucoin-Barry D, Manuelian D, Monbouquette R, Reisman M, Gray W, Block PC, Block EH, Ladenheim M, Simon DI. Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA. Am J Cardiol 2003; 92: 1492–1494
   PubMed Web of Science ®Google Scholar
• Alberts MJ, Bergman DL, Molner E, Jovanovic BD, Ushiwata I, Teruya J. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 2004; 35: 175–178
   PubMed Web of Science ®Google Scholar
• Chen W-H, Lee P-Y, Ng W, Tse H-F, Lau C-P. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004; 43: 1127–1129
   PubMedGoogle Scholar
• Macchi L, Christiaens L, Brabant S, Sorel N, Allal J, Mauco G, Brizard A. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 2002; 107: 45–49
   PubMed Web of Science ®Google Scholar
• Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230–235
   PubMed Web of Science ®Google Scholar
• Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961–965
   PubMed Web of Science ®Google Scholar
• Jilma B. Platelet function analyzer (PFA-100): A tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 2001; 138: 152–163
   PubMed Web of Science ®Google Scholar
• Fuchs I, Frossard M, Spiel A, Riedmüller, Laggner AN, Jilma B. Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS. J Thromb Haemost 2006; 4: 2547–2552
   PubMed Web of Science ®Google Scholar
• Malek LA, Spiewak M, Filipiak KJ, Grabowski M, Szpotanska M, Rosiak M, Glowczynska R, Imiela T, Huczek Z, Opolski G. Persistent platelet activation is related to very early cardiovascular events in patients with acute coronary syndromes. Kardiol Pol 2007; 65: 40–45
   PubMed Web of Science ®Google Scholar
• Sambola A, Heras M, Escolar G, Lozano M, Pino M, Martorell T, Torra M, Sanz G. The PFA-100® detects sub-optimal antiplatelet responses in patients on aspirin. Platelets 2004; 15: 439–446
   PubMed Web of Science ®Google Scholar
• Campo G, Valgimigli M, Gemmati D, Percoco G, Tognazzo S, Cicchitelli G, Catozzi L, Malagutti P, Anselmi M, Vassanelli C, et al. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention. Insights into the STRATEGY study. J Am Coll Cardiol 2006; 48: 2178–2185
   PubMed Web of Science ®Google Scholar
• Ziegler S, Maca T, Alt E, Speiser W, Schneider B, Minar E. Monitoring of antiplatelet therapy with the PFA-100® in peripheral angioplasty patients. Platelets 2002; 13: 493–497
   PubMed Web of Science ®Google Scholar
• Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332: 635–641
   PubMed Web of Science ®Google Scholar
• Furman MI, Benoit SE, Barnard BS, Valeri CR, Borbone ML, Becker RC, Hechtman HB, Michelson AD. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol 1998; 31: 352–358
   PubMed Web of Science ®Google Scholar
• Macchi L, Christiaens L, Brabant S, Sorel N, Ragot S, Allal J, Mauco G, Brizard A. Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with 807T (GP Ia/IIa) and C-5T Kozak (GP Ibα) polymorphisms. J Am Coll Cardiol 2003; 42: 1115–1119
   PubMed Web of Science ®Google Scholar
• Lanza GA, Sestito A, Iacovella S, Morlacchi L, Romagnoli E, Schiavoni G, Crea F, Maseri A, Andreotti F. Relation between platelet response to exercise and coronary angiographic findings in patients with effort angina. Circulation 2003; 107: 1378–1382
   PubMed Web of Science ®Google Scholar
• Cattaneo M. Aspirin and clopidogrel. Efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004; 24: 1980–1987
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494–502
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Berger PB, Mann III JT, Fry ET, DeLago A, Wilmer C, Topol EJ. CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 2002; 288: 2411–2420
   PubMed Web of Science ®Google Scholar
• Bhatt DL, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006; 354: 1706–17
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Jarcho JA. The Charisma of subgroups and the subgroups of Charisma. N Engl J Med 2006; 354: 1744–1746
   PubMedGoogle Scholar
• Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171–3175
   PubMed Web of Science ®Google Scholar
• Gianetti J, Parri MS, Sbrana S, Paoli F, Maffei S, Paradossi U, Berti S, Clerica A, Biagini A. Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: A 6 months prospective study. Thromb Res Dec 15, 2005, available on line
   PubMedGoogle Scholar
• Eikelboom JW, Hirsch J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650–1655
   PubMed Web of Science ®Google Scholar